Biotech Sector: Street Noticing Real Assets, Says Mizuho Strategist Jared Holz

Shifting Sentiment in Biotech

• 💡 The primary driver for a shift in sentiment in the biotech sector is the index stopping its consistent daily decline.
• ⚠️ Significant damage has been done to the XBI and biotech stocks over the past few years, making any upward movement notable.

Unique Nature of Biotech Stocks

• 🧩 It's a mistake to lump all biotech stocks together as they are largely mutually exclusive and unique.
• 🎯 Making a directional call on the overall biotech index has been challenging due to the distinct nature of each company.

Identifying Undervalued Assets

• 📈 Despite past market performance where biotech is up only 20% over 10 years compared to the market tripling, there is evidence of upside potential.
• 💰 The selling has subsided, and the underlying stories and real assets within biotech companies are finally being better appreciated.

Promising Biotech Companies

• 🚀 Argenics is highlighted as a company with significant upside potential, despite its stock already performing well.
• ⚡ Cytokinetics also showed strong performance, with potential for further upside.
• 📌 Companies like Inimemed have graduated from small-cap to large-cap status (over $25 billion), demonstrating the growth of real assets serving large markets.
• 🎯 Argenics is noted for serving very big markets and having a product launch underway, evolving into a large-cap biotech similar to Gilead and Vertex.